|
| | 103RD GENERAL ASSEMBLY
State of Illinois
2023 and 2024 HB5420 Introduced 2/9/2024, by Rep. Kimberly Du Buclet SYNOPSIS AS INTRODUCED: | | | Amends the Newborn Metabolic Screening Act. Provides for the screening and testing of all newborns for Guanidinoacetate Methyltransferase (GAMT) deficiency. Sets forth requirements that must be met before the screening and testing begin. Authorizes the Department of Public Health to implement an additional fee for the screening prior to beginning testing in order to accumulate resources to implement the amendatory Act. |
| |
| | A BILL FOR |
|
|
| | HB5420 | | LRB103 37927 CES 68059 b |
|
|
1 | | AN ACT concerning health. |
2 | | Be it enacted by the People of the State of Illinois, |
3 | | represented in the General Assembly: |
4 | | Section 5. The Newborn Metabolic Screening Act is amended |
5 | | by adding Section 3.6 as follows: |
6 | | (410 ILCS 240/3.6 new) |
7 | | Sec. 3.6. Guanidinoacetate Methyltransferase (GAMT) |
8 | | deficiency. |
9 | | (a) In accordance with the timetable specified in this |
10 | | Section, the Department shall provide all newborns with |
11 | | screening tests for the presence of Guanidinoacetate |
12 | | Methyltransferase (GAMT) deficiency. The testing shall begin |
13 | | within 12 months after the occurrence of all of the following: |
14 | | (1) the establishment and verification of relevant and |
15 | | appropriate performance specifications as defined under |
16 | | the federal Clinical Laboratory Improvement Amendments and |
17 | | regulations thereunder for Federal Drug |
18 | | Administration-cleared or in-house developed methods, |
19 | | performed under an institutional review board approved |
20 | | protocol, if required; |
21 | | (2) the availability of quality assurance testing and |
22 | | comparative threshold values for GAMT; |
23 | | (3) the acquisition and installment by the Department |